key: cord-0903276-mfnjlpyn authors: Kitagawa, Yutaro; Imai, Kazuo; Matsuoka, Masaru; Fukada, Ai; Kubota, Katsumi; Sato, Momoko; Takada, Tomohito; Noguchi, Sakiko; Tarumoto, Norihito; Maesaki, Shigefumi; Takeuchi, Shinichi; Maeda, Takuya title: Evaluation of the correlation between the access SARS‐CoV‐2 IgM and IgG II antibody tests with the SARS‐CoV‐2 surrogate virus neutralization test date: 2021-10-05 journal: J Med Virol DOI: 10.1002/jmv.27338 sha: f6b467afe91031e20862462371d421238af3aeaa doc_id: 903276 cord_uid: mfnjlpyn Fully automated immunoassays for detecting severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) antibodies that are strongly correlated with neutralization antibodies (nAbs) are clinically important because they enable the assessment of humoral immunity after infection and vaccination. Access SARS‐CoV‐2 immunoglobulin M (IgM) and immunoglobulin G (IgG) II antibody tests are semi‐quantitative, fully automated immunoassays that detect anti‐receptor‐binding domain (RBD) antibodies and might reflect nAb levels in coronavirus disease 2019 (COVID‐19). However, no studies have investigated the clinical utility of these tests in association with nAbs to date. To evaluate the clinical utility of Access SARS‐CoV‐2 IgM and IgG II antibody tests and their correlation with the SARS‐CoV‐2 surrogate virus neutralization test (sVNT) that measures nAbs in patients with COVID‐19, we analyzed 54 convalescent serum samples from COVID‐19 patients and 89 serum samples from non‐COVID‐19 patients. The presence of anti‐RBD antibodies was detected using Access SARS‐CoV‐2 IgM and IgG II antibody tests, while nAbs were measured by sVNT. The sensitivity and specificity of sVNT were 94.4% and 98.9%, respectively. There were strong positive correlations between the inhibition values of sVNT and the results of the Access SARS‐CoV‐2 IgM (R = 0.95, R (2) = 0.90, p < 0.001) and IgG II antibody tests (R = 0.96, R(2) = 0.92, p < 0.001). In terms of the presence of nAbs, the sensitivity and specificity were 98.1% and 98.9% in the IgM assay and 100.0% and 100.0% in the IgG II assay, respectively. The Access SARS‐CoV‐2 IgM and IgG II antibody tests showed high sensitivity and specificity for the detection of nAbs in COVID‐19 patients and might be alternatives for measuring nAbs. Coronavirus disease 2019 (COVID-19) is an emerging disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The spike (S) and nucleocapsid (N) structural proteins of SARS-CoV-2 are currently the main targets for antibody testing. The S protein contains two subunits (S1 and S2), and the receptor-binding domain (RBD) in S1 is responsible for the recognition of angiotensinconverting enzyme-2, a human cell surface receptor. 1 Because antibodies specific for the RBD in S1 can neutralize SARS-CoV-2 by inhibiting its entry into host cells, anti-RBD antibodies work as protective immune and neutralizing antibodies (nAbs). 2, 3 Several effective vaccines have been developed using the S protein and vaccination programs have started worldwide. [4] [5] [6] [7] Serological assays for detecting anti-RBD antibodies and nAbs are becoming increasingly important for the evaluation of humoral immunity against SARS-CoV-2 not only after vaccination but also in past infections. Currently, there is widespread use of fully automated immunoassays for the detection of anti-SARS-CoV-2 antibodies with high sensitivity and specificity. Conventional neutralization assays require trained staff, specific equipment, and time-consuming methods. The association between the results of fully automated immunoassays for anti-SARS-CoV-2 antibodies and the presence of nAbs has mainly been explored because those assays are used as substitutes for neutralization assays. Although several assays are indeed useful to assess protective immunity against SARS-CoV-2, there is wide variability in their correlation with nAbs. 8 [16] [17] [18] [19] [20] and stored at −80°C until use. We also analyzed 89 serum samples collected from 89 patients with fever at Saitama Medical University Hospital in Japan, from February 11, 2020 to December 31, 2020. All patients were negative for SARS-CoV-2 at least once by RT-qPCR and were then clinically diagnosed by their doctor as having a disease other than COVID-19. Briefly, the patients ranged in age from 20 to 93 years (median: 73 years; IQR: 48-82 years); there were 49 men (55.1%) and 40 women (44.9%). All serum samples were stored at −80°C until use. IgM and IgG antibody assays against the SARS-CoV-2 RBD protein were performed using the Access SARS-CoV-2 IgM and IgG II Anti- To measure nAbs against RBD of SARS-CoV-2, the SARS-CoV-2 surrogate virus neutralization test (sVNT) (GenScript) was used. For this assay, each serum sample was diluted 1/10 in sample dilution buffer, and an equal volume of horseradish peroxidase-conjugated RBD solution was added to each diluted sample according to the manufacturer's instructions; each sample was tested in duplicate. To perform accurate correlation analysis, serum samples must be diluted appropriately to capture the entire linear range, but in this study, the sample dilution was fixed to 1/10 in accordance with the provided instructions. After incubation at 37°C for 30 min, 100 µl of each sample was added to the wells of a 96-well plate and incubated at 37°C for 30 min. The plates were washed four times with wash solution. The enzymatic reaction was developed with 100 µl/well TMB solution at 25°C for 15 min. Thereafter, the reaction was stopped using a 50 µl/well stop solution, and the plates were read at 450 nm using an enzyme-linked immunosorbent assay reader. The inhibition rate (%) was determined using the following formula: (1 − sample OD450 value/negative control OD450 value) × 100, according to the manufacturer's instructions. According to the manufacturer's instructions, the cut-off value for sVNT for the presence of SARS-CoV-2 nAbs is inhibition ≥20%. However, sVNT has not been validated in the Japanese population. Therefore, we determined the optimal cut-off value for our patient population as recommended by the manufacturer (https://www. genscript.com/). The optimal cut-off value for sVNT was determined by maximizing Youden's index based on the receiver operating characteristic (ROC) curves using the COVID-19-positive (n = 54) and -negative (n = 89) samples. Continuous variables are expressed as the mean and SD or median and IQR and were compared using the t test and the Wilcoxon ranksum test for parametric and nonparametric data, respectively. Linear regression analysis was used to assess the relationship between each continuous variable. Rho values were analyzed by the Spearman rank-order correlation coefficient. A two-sided p value <0.05 was considered statistically significant. All statistical analyses were conducted using R (v4.0.2; R Foundation for Statistical Computing, Vienna, Austria; http://www.R-project.org/). Distributions of S/CO and AU/ml for the Access IgM and IgG II assays for COVID-19 and non-COVID-19 sera are shown in Figure 1A ,B, respectively. In the IgM assay, the median S/CO value of the COVID-19 samples was 16 The alternative cut-off value for sVNT was determined using serum | 337 curve of sVNT was 0.99, and the alternative cut-off value was determined to be ≥30% inhibition ( Figure 2B) . Sensitivity was 94.4% (95% CI: 84.6%-98.8%) and specificity was 98.9% (95% CI: 93.9%-99.9%) when using the alternative cut-off value of ≥30% inhibition, and 94.4% (95% CI: 84.6%-98.8%) and 93.3% (95% CI: 85.9%-97.5%), respectively, when using the ≥20% inhibition cut-off value provided by the manufacturer (Table 1) . One non-COVID-19 patient was confirmed positive by both the sVNT and the IgG II antibody assay. Finally, 52 and 91 serum samples were determined to be positive and negative by sVNT, respectively. that nAb titers correlated strongly with disease severity and then declined rapidly after recovery compared with anti-spike IgG levels. 23 Therefore, large-scale multi-national investigations are still required to determine whether the Access SARS-CoV-2 IgG II antibody test might be a suitable substitute for the nAb assay. The Access SARS-CoV-2 IgM and IgG II antibody tests showed high sensitivity and specificity for the detection of anti-SARS-CoV-2 antibodies in COVID-19 and also showed strong positive correlations with the results of sVNT. In particular, the Access SARS-CoV-2 IgG II antibody test might be an alternative to an nAb assay as a surveillance tool. We thank the clinical laboratory technicians and all members of the COVID-19 Task Force at Saitama Medical University Hospital. The authors declare that there are no conflict of interests. The data that support the findings of this study are available from the corresponding author upon reasonable request. http://orcid.org/0000-0002-8416-7371 Takuya Maeda http://orcid.org/0000-0003-0912-4643 Structure of SARS coronavirus spike receptor-binding domain complexed with receptor Human neutralizing antibodies elicited by SARS-CoV-2 infection A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK Safety and efficacy of an rAd26 and rAd5 vector-based heterologous primeboost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia Analytical and clinical performances of five immunoassays for the detection of SARS-CoV-2 antibodies in comparison with neutralization activity Longitudinal serological analysis and neutralizing antibody levels in coronavirus disease 2019 convalescent patients Evaluation of high-throughput SARS-CoV-2 serological assays in a longitudinal cohort of patients with mild COVID-19: clinical sensitivity, specificity and association with virus neutralization test Association between SARS-CoV-2 neutralizing antibodies and commercial serological assays Clinical and analytical performance of an automated serological test that identifies S1/S2-neutralizing IgG in COVID-19 patients semiquantitatively SARS-CoV-2 neutralization and serology testing of COVID-19 convalescent plasma from donors with nonsevere disease Multicenter evaluation of the clinical performance and the neutralizing antibody activity prediction properties of ten high throughput serological assays used in clinical laboratories 19-emergency-use-authori zations-medical-devices/eua-authorized-serology-test-performance Development of genetic diagnostic methods for detection for novel coronavirus 2019(nCoV-2019) in Japan Evaluation of a commercially-available surrogate virus neutralization test for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) National SARS-CoV-2 Serology Assay Evaluation Group. Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison Humoral Immune Response to SARS-CoV-2 in Iceland Insight into the practical performance of RT-PCR testing for SARS-CoV-2 using serological data: a cohort study Frequency of serological nonresponders and false-negative RT-PCR results in SARS-CoV-2 testing: a population-based study A longitudinal study of SARS-CoV-2-infected patients reveals a high correlation between neutralizing antibodies and COVID-19 severity